Abstract:Alzheimer's disease is a rather complex neurodegenerative disease, which is attributed to a combination of multiple factors. Among the many pathological pathways, synaptic dysfunctions, such as synapses loss and deficits in synaptic plasticity, were thought to be strongly associated with cognitive decline. The deficiencies in various sorts of neurotransmissions are responsible for the multifarious neurodegenerative symptoms in Alzheimer's disease, for example, the cholinergic and glutamatergic deficits for cognitive decline, the excitatory and inhibitory neurotransmission dyshomeostasis for synaptic plasticity deficits and epileptiform symptoms, and the monoamine neurotransmission for neuropsychiatric symptoms. Amyloid cascade hypothesis is the most popular pathological theory to explain Alzheimer's disease pathogenesis and attracts considerable attention. Multiple lines of genetic and pathological evidence support the predominant role of amyloid beta in Alzheimer's disease pathology. Neurofibrillary tangles assembled by microtubule-associated protein tau are other important histopathological characteristics in Alzheimer's disease brains. Cascade of tau toxicity was proved to lead to neuron damage, neuroinflammation and oxidative stress in brain. Ageing is the main risk factor of neurodegenerative diseases, and is associated with inflammation, oxidative stress, reduced metabolism, endocrine insufficiencies and organ failures. These aging related risk factors were also proved to be some of the risk factors contributing to Alzheimer's disease. In Alzheimer's disease drug development, many good therapeutic strategies have been investigated in clinical evaluations. However, complex mechanism of Alzheimer's disease and the interplay among different pathological factors call for the come out of all-powerful therapies with multiple curing functions. This review seeks to summarize some of the representative treatments targeting different pathological pathways currently under clinical evaluations. Multi-target therapies as an emerging strategy for Alzheimer's disease treatment will be highlighted.

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Targeting Synaptic Pathology in Alzheimer’s Disease

Tau Acts in Concert With Kinase/Phosphatase Underlying Synaptic Dysfunction

Roles of O-GlcNAcylation on amyloid-β precursor protein processing, tau phosphorylation, and hippocampal synapses dysfunction in Alzheimer’s disease

Synaptic tau: A pathological or physiological phenomenon?

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Oligomeric Aβ-induced Synaptic Dysfunction in Alzheimer’s Disease

Role of Microtubule-Associated Protein Tau Phosphorylation in Alzheimer’s Disease

Pathological mechanisms and therapeutic strategies for Alzheimer’s disease

Role of APP and Aβ in Synaptic Physiology.

Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential

Tau Abnormalities and the Potential Therapy in Alzheimer’s Disease

Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT×P301S transgenic mice at the early stage of Alzheimer's disease

Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy

Apolipoprotein E in Alzheimer's Disease: Focus on Synaptic Function and Therapeutic Strategy

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

The synapse as a treatment avenue for Alzheimer’s Disease

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

Dysfunction of NMDA receptors in Alzheimer’s disease

Advances in the Pathogenesis of Alzheimer’s Disease: Focusing on Tau-Mediated Neurodegeneration